papers

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

BMJ 346:f2267.

Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB, Canada

OBJECTIVE: To determine if the use of sitagliptin in newly treated patients with type 2 diabetes is associated with any changes in clinical outcomes.

DESIGN: Retrospective population based cohort study.

SETTING: Large national commercially insured US claims and integrated laboratory database.

PARTICIPANTS: Inception cohort of new users of oral antidiabetic drugs between 2004 and 2009 followed until death, termination of medical insurance, or December 31 2010.

MAIN OUTCOME MEASURE: Composite endpoint of all cause hospital admission and all cause mortality, assessed with time varying Cox proportional hazards regression after adjustment for demographics, clinical and laboratory data, pharmacy claims data, healthcare use, and time varying propensity scores.

RESULTS: The cohort included 72,738 new users of oral antidiabetic drugs (8032 (11%) used sitagliptin; 7293 (91%) were taking it in combination with other agents) followed for a total of 182,409 patient years. The mean age was 52 (SD 9) years, 54% (39,573) were men, 11% (8111) had ischemic heart disease, and 9% (6378) had diabetes related complications at the time their first antidiabetic drug was prescribed. 14,215 (20%) patients met the combined endpoint. Sitagliptin users showed similar rates of all cause hospital admission or mortality to patients not using sitagliptin (adjusted hazard ratio 0.98, 95% confidence interval 0.91 to 1.06), including patients with a history of ischemic heart disease (adjusted hazard ratio 1.10, 0.94 to 1.28) and those with estimated glomerular filtration rate below 60 mL/min (1.11, 0.88 to 1.41).

CONCLUSIONS: Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in this cohort were concordant with clinical practice guidelines, in that it was used as add-on treatment.

Comment in

• Authors’ reply to de Oliveira.Eurich DT, S Simpson, C V Asche, A Senthilselvan, F A McAlister, and J K Sandhu-Minhas. BMJ. 2013 Jun 4; 346:f3579. Epub 2013 Jun 4.
• Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?  de Oliveira JM. BMJ. 2013 Jun 4; 346:f3568. Epub 2013 Jun 4.
• Should we be reassured about sitagliptin?Segal J. BMJ. 2013 May 14; 346:f3051. Epub 2013 May 14.

PMID: 23618722
PMCID: PMC3635468